AI Planning Tools for Lung Cancer Team Care
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether artificial intelligence can help doctors plan better treatment for non-small cell lung cancer (NSCLC). A team of specialists will use AI tools alongside their usual approach to see if it improves care and safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- Your doctors believe you need systemic treatment (medicine that travels throughout your body, like chemotherapy or targeted therapy)
- You have complete medical records, imaging scans (CT, PET), and tumor testing results available
- You have non-small cell lung cancer (NSCLC), not another type of lung or chest tumor
- Your cancer is stage II, III, or IV (not early-stage stage I)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses an AI system that looks at your PET/CT scan images to figure out the exact type and genetic makeup of your non-small cell lung cancer. The goal is to improve how doctors classify and treat your cancer without needing extra invasive tests.
This trial tests whether using AI to help radiologists read lung CT scans can find cancer earlier and lower healthcare costs. You may qualify if you are at risk for lung cancer and have not been screened recently.
This trial uses artificial intelligence to predict if early-stage lung cancer has spread to nearby lymph nodes. It aims to help doctors make better treatment decisions for patients with stage 1 lung cancer.
This trial tests an artificial intelligence platform that helps doctors predict if lymph nodes in the chest contain cancer during a routine ultrasound procedure. It aims to make staging more accurate for people with suspected or confirmed non-small cell lung cancer.
This study tests an artificial intelligence (AI) system that uses your health information and medical images to better judge cancer risk and support diagnosis and treatment decisions. It may help doctors make more consistent assessments by combining clinical records, imaging, and other lab-style data.
This trial is testing whether artificial intelligence can help predict how well people with advanced non-small cell lung cancer (NSCLC) respond to immunotherapy or chemo-immunotherapy. If you have stage IV NSCLC and have started this treatment, your data may help build a better prediction tool.
Hear when a new Nonsmall Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.